The global deep brain stimulation (DBS) devices market for Parkinson’s disease was valued at US$ 0.85 Bn in 2020 and is projected to expand at a CAGR of 5.1% from 2021 to 2028, surpassing US$ 1.2 Bn by the end of 2028. Increasing adoption of surgical treatments, a growing geriatric population, and favorable reimbursement policies are expected to support market expansion. Furthermore, technological advancements in implantable pulse generators (IPGs) and the growing use of telehealth solutions are creating opportunities for manufacturers.

According to analysts at Transparency Market Research (TMR), companies must prioritize research and development to improve battery longevity, device reliability, recharging convenience, and programming capabilities. Optimizing electrode materials, lead configurations, and implantation techniques will also be important for improving treatment outcomes and strengthening competitive positioning.

Market Introduction

Parkinson’s disease is a chronic, progressive neurological disorder associated with the loss of dopamine-producing neurons in the substantia nigra region of the midbrain. Common symptoms include tremors, bradykinesia, akinesia, and postural instability. As the disease progresses, patients may experience increasing difficulty managing symptoms through conventional medication alone.

Deep brain stimulation is a surgical treatment that involves implanting electrodes in specific areas of the brain and connecting them to a programmable pulse generator. The device delivers electrical impulses to targeted neural circuits to help manage movement-related symptoms. DBS therapy is particularly relevant for selected patients with advanced Parkinson’s disease whose symptoms are inadequately controlled by medication.

The growing need for effective long-term symptom management is encouraging healthcare professionals to consider DBS as part of comprehensive treatment strategies. Improvements in device design, surgical techniques, and postoperative programming are expected to contribute to market growth.

Key Growth Drivers

Increasing Adoption of Surgical Therapy

The limitations of drug therapy are encouraging patients and healthcare professionals to consider DBS for eligible cases of advanced Parkinson’s disease. Although medications remain an important component of treatment, their effectiveness may fluctuate over time, and some patients experience adverse effects or motor complications.

DBS can help manage specific symptoms in appropriately selected patients and may reduce medication-related complications. Growing awareness of these benefits, along with advances in minimally invasive surgical techniques, is expected to support demand for DBS devices. However, treatment selection depends on individual clinical conditions, and DBS is not suitable for every patient.

Government Initiatives and Favorable Reimbursement Policies

Government initiatives aimed at improving neurological healthcare, expanding access to advanced medical technologies, and strengthening healthcare infrastructure can support market development. Favorable reimbursement policies may also reduce the financial burden associated with device implantation and related treatment.

The increasing prevalence of neurological disorders, including Parkinson’s disease, tremors, and other movement disorders, is encouraging healthcare providers to explore advanced therapeutic options. At the same time, the growing geriatric population is increasing demand for specialized neurological care. These factors are expected to create opportunities for manufacturers, hospitals, and neurological clinics.

Market Trends and Opportunities

Commercialization of Portable and Affordable Devices

Manufacturers are focusing on developing DBS systems that are easier for physicians to implant, program, and maintain while remaining convenient for patients. Improvements in portability, battery performance, device efficiency, and programming flexibility could enhance the overall treatment experience.

Rechargeable implantable pulse generators and advances in stimulation technologies represent important areas for innovation. Companies are also investing in research and development to improve reliability and reduce the need for device-related interventions. Meanwhile, products undergoing clinical trials could expand the competitive landscape if they demonstrate safety, efficacy, and commercial viability.

Telehealth and Remote Patient Monitoring

The coronavirus pandemic highlighted the importance of telehealth and eHealth applications in managing patients with chronic neurological conditions. Restrictions on in-person consultations disrupted some outpatient neurological services, increasing the need for remote communication and follow-up.

Telehealth platforms can help healthcare professionals monitor symptoms, review treatment progress, and provide consultations when in-person visits are difficult. Digital health tools may also support continuity of care for patients using DBS systems. However, remote monitoring complements rather than replaces necessary clinical assessments, device programming procedures, and emergency care.

The integration of digital health technologies with neurological treatment is creating opportunities for medical technology companies to improve patient support and healthcare delivery.

Infection Risks and Device Limitations

Despite its advantages, DBS therapy involves surgical risks that may limit adoption. Infection associated with implantable pulse generators is an important concern, as complications can require additional treatment or device removal.

Manufacturers and healthcare providers can address these challenges through improved device design, appropriate surgical techniques, infection-prevention protocols, and patient education. Research into longer-lasting batteries, smaller device profiles, and more reliable charging systems may further improve acceptance.

Regional Outlook

North America is projected to dominate the global deep brain stimulation devices market for Parkinson’s disease, accounting for approximately 38.60% of the market by 2028. The regional market is anticipated to reach US$ 0.48 Bn by the end of the forecast period.

This position is supported by the adoption of DBS surgical therapy, a growing geriatric population, established healthcare infrastructure, and favorable reimbursement policies. Awareness of advanced neurological treatments and the availability of specialized healthcare professionals are additional factors supporting regional demand.

Europe is also expected to contribute to market growth through its established healthcare systems and access to neurological treatment. Meanwhile, Asia Pacific, Latin America, and the Middle East and Africa offer potential opportunities as awareness and healthcare infrastructure improve. However, high device costs, limited reimbursement coverage, and uneven access to specialized treatment may constrain adoption in these regions.

Market Segmentation

The global DBS devices market for Parkinson’s disease is segmented by product type, end user, and region.

By product type, the market includes single-channel and dual-channel deep brain stimulators. Demand across these categories is influenced by clinical requirements, stimulation capabilities, and physician preferences.

By end user, the market comprises hospitals, ambulatory surgical centers, neurological clinics, and other healthcare facilities. Hospitals are important providers of DBS implantation procedures because of their surgical infrastructure and access to multidisciplinary specialists.

Regionally, the market covers North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Competitive Landscape

Major companies operating in the market include Medtronic, Inc., St. Jude Medical, Inc., and Boston Scientific Corporation. Their DBS product portfolios have included systems such as Activa, Libra, and Vercise. Other companies identified in the competitive landscape include Aleva Neurotherapeutics SA, Adaptive Neuromodulation GmbH, NeuroSigma, Inc., and NeuroPace, Inc.

Market participants are focusing on product innovation, research and development, device reliability, affordability, and ease of use. Clinical research and improvements in stimulation technology are expected to influence future competition. Companies that address patient needs while maintaining high standards of safety and clinical performance may strengthen their market positions.

Future Outlook

The deep brain stimulation devices market for Parkinson’s disease is expected to experience steady growth through 2028. Rising demand for advanced neurological treatments, increasing adoption of surgical therapy, supportive reimbursement policies, and technological innovation are likely to remain important growth factors. Continued investment in safer, more reliable, and patient-friendly devices will be essential for expanding access to DBS therapy and addressing the evolving needs of patients with Parkinson’s disease.